

## COMPANY OVERVIEW

Cocrystal Pharma, Inc. is a clinical stage biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of hepatitis C viruses, influenza viruses, noroviruses and coronaviruses. We employ unique structure-based technologies and Nobel Prize winning expertise to create first- and best-in-class antiviral drugs. The Company is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). CC-31244 is currently being evaluated in a Phase 2a study for the treatment of hepatitis C as part of a cocktail for ultra-short therapy of 4 to 6 weeks. Cocrystal recently entered into an exclusive worldwide license and collaboration agreement with Merck & Co., Inc. to discover and develop certain proprietary influenza A/B antiviral agents. CC-42344, the Company's molecule for the treatment of influenza A, is currently being evaluated in preclinical IND-enabling studies. In addition, the Company has a pipeline of promising early discovery program to identify and develop novel antivirals for the treatment of norovirus gastroenteritis.

## RECENT NEWS

### Cocrystal Pharma Announces Closing of \$6.8 Million Registered Direct Offering Priced At-the-Market

Mar 11 2020, 9:40 AM EDT

### Cocrystal Pharma Announces \$6.8 Million Registered Direct Offering Priced At-the-Market

Mar 9 2020, 3:00 PM EDT

### Cocrystal Pharma Announces Plans to Advance Coronavirus Program

Mar 6 2020, 4:01 PM EST

## STOCK OVERVIEW

|               |                   |
|---------------|-------------------|
| Symbol        | COCP              |
| Exchange      | Nasdaq            |
| Market Cap    | 39.89m            |
| Last Price    | \$0.765           |
| 52-Week Range | \$0.3861 - \$2.95 |

03/27/2020 04:00 PM EDT

## INVESTOR RELATIONS

JTC Team, LLC  
Jenene Thomas  
T: 833-475-8247  
[cocp@jtcir.com](mailto:cocp@jtcir.com)

## MANAGEMENT TEAM

### Gary Wilcox, Ph.D.

Chairman of the Board and Chief Executive Officer

### Sam Lee, Ph.D.

President

### James J. Martin

Chief Financial Officer

---

## COCRYSTAL PHARMA, INC.

19805 N. Creek Parkway  
Bothell, WA 98011  
US

---

## DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.